Cabaletta Bio Registered Logo.png
Cabaletta Bio Announces Appointment of Michael Gerard as General Counsel
September 07, 2021 08:00 ET | Cabaletta Bio
PHILADELPHIA, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies...
Cabaletta Bio Registered Logo.png
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
September 02, 2021 08:00 ET | Cabaletta Bio
PHILADELPHIA, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies...
Cabaletta Bio Registered Logo.png
Cabaletta Bio Reports Clinical Data from the Second Dose Cohort in DesCAARTes™ Trial in Patients with mPV
August 18, 2021 07:00 ET | Cabaletta Bio
– No dose-limiting toxicities (DLTs) or clinically relevant adverse events observed as of August 17 using 100 million cells in the second dose cohort – – DSG3-CAART persistence observed in all three...
Cabaletta Bio Registered Logo.png
Cabaletta Bio Reports Second Quarter 2021 Financial Results and Provides Business Update
August 05, 2021 07:30 ET | Cabaletta Bio
       – Company continues to make progress on the DesCAARTes™ trial for DSG3-CAART; expects to report second and third cohort safety data in 3Q21 and 4Q21, respectively, and data on target engagement...
Cabaletta Bio Registered Logo.png
Cabaletta Bio Appoints Biopharmaceutical Leader Scott Brun, M.D. to Board of Directors
June 28, 2021 08:00 ET | Cabaletta Bio
Dr. Brun’s early and late-stage clinical development expertise in autoimmune, neurologic, and renal disease areas aligns well with Cabaletta’s rapidly emerging pipeline PHILADELPHIA, June 28, 2021 ...
Cabaletta Bio Registered Logo.png
Cabaletta Bio to Present at the Jefferies Healthcare Conference
May 27, 2021 08:00 ET | Cabaletta Bio
PHILADELPHIA, May 27, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for...
Cabaletta Bio Registered Logo.png
Cabaletta Bio Reports First Quarter 2021 Financial Results and Provides New Pipeline Updates
May 03, 2021 07:05 ET | Cabaletta Bio
– Acute safety data from the first cohort in the DesCAARTes™ trial announced today; no dose limiting toxicities (DLTs) or clinically relevant adverse events observed in the first dose cohort as of...
Cabaletta Bio Registered Logo.png
Cabaletta Bio Reports Acute Safety Data from the First Dose Cohort in DesCAARTes™ Trial
May 03, 2021 07:00 ET | Cabaletta Bio
– No dose limiting toxicities (DLTs) or clinically relevant adverse events observed in the first dose cohort as of April 30, 2021 – – Second dose cohort to be initiated after the third patient...
Cabaletta Bio Registered Logo.png
Cabaletta Bio to Present at the 20th Annual Needham Healthcare Conference
April 07, 2021 08:00 ET | Cabaletta Bio
PHILADELPHIA, April 07, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies...
logo.png
Cabaletta Bio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Business Update
March 16, 2021 07:30 ET | Cabaletta Bio
PHILADELPHIA, March 16, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies...